BOUCHERVILLE, QC, March 31, 2016 (GLOBE NEWSWIRE) -- Sandoz Canada Inc. announced the launch of PrTOBRAMYCIN INHALATION SOLUTION, an authorized generic version of PrTOBI*, currently marketed by Novartis Pharmaceuticals Canada Inc. PrTOBRAMYCIN INHALATION SOLUTION, a respiratory antibiotic, is indicated for the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections.
"We are proud to bring an authorized generic version of PrTOBI* to Canadian patients with cystic fibrosis and suffering from chronic pulmonary infections," said Michel Robidoux, President and General Manager of Sandoz Canada Inc. "This launch is in line with our commitment to offer high-quality, affordable medicines in order to facilitate patient access to healthcare."
Cystic fibrosis is a life-threatening genetic disease that primarily affects the lungs and digestive system. According to Cystic Fibrosis Canada, more than 4,000 Canadian adults and children have the disease.
*PrTOBI is a registered trademark of Novartis Vaccines and Diagnostics Inc.
Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as "new", or similar expressions, or by express or implied discussions regarding potential new indications or labeling for Sandoz PrTOBRAMYCIN INHALATION SOLUTION or regarding potential future revenues from Sandoz PrTOBRAMYCIN INHALATION SOLUTION. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Sandoz PrTOBRAMYCIN INHALATION SOLUTION to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Sandoz PrTOBRAMYCIN INHALATION SOLUTION will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Sandoz PrTOBRAMYCIN INHALATION SOLUTION could be affected by, among other things, new clinical data or additional analysis of existing data, unexpected regulatory actions or delays or government regulation generally; uncertainties regarding actual or potential legal proceedings, including, among others, intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling Sandoz PrTOBRAMYCIN INHALATION SOLUTION, and the uncertain outcome of any such litigation; the particular prescribing preferences of physicians and patients; competition in general; government, industry and general public pricing pressures; unexpected manufacturing difficulties or delays; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sandoz is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Sandoz
Sandoz, a Novartis company, is a global leader in generic pharmaceuticals and biosimilars, driving sustainable access to high-quality healthcare. Sandoz supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe. The Sandoz portfolio comprises approximately 1,100 molecules, which accounted for 2015 sales of USD 9.2 billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area. The company holds leading global positions in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines.